XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Intangible Assets - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2018
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2018
Dec. 31, 2022
Mar. 04, 2022
May 31, 2021
Finite-Lived Intangible Assets [Line Items]                
Amortization expenses     $ 600 $ 900        
Amortization expenses, remainder period     1,800          
Amortization expenses, 2024     2,400          
Amortization expenses, 2025     2,400          
Amortization expenses, 2026     2,400          
Amortization expenses, 2027     2,400          
Amortization expenses, thereafter     16,700          
Capitalization of finite-lived intangible asset     32,500     $ 32,500    
Other accrued liabilities     22,223     25,190 [1]    
Other long-term liabilities     17,501     26,643 [1]    
Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc                
Finite-Lived Intangible Assets [Line Items]                
Capitalization of finite-lived intangible asset               $ 12,500
Payment Following FDA Approval of Truseltiq                
Finite-Lived Intangible Assets [Line Items]                
Capitalization of finite-lived intangible asset               $ 20,000
QED Therapeutics, Inc                
Finite-Lived Intangible Assets [Line Items]                
Other accrued liabilities     2,500     2,500    
Other long-term liabilities     $ 8,500     $ 8,500    
QED Therapeutics, Inc | Foundation Medicine Diagnostics Agreement | Foundation Medicine, Inc                
Finite-Lived Intangible Assets [Line Items]                
Potential regulatory milestone payments $ 12,500              
Regulatory milestone payments term 4 years              
QED Therapeutics, Inc | Maximum                
Finite-Lived Intangible Assets [Line Items]                
Potential regulatory milestone payments         $ 60,000      
Potential sales milestone payments         35,000      
Origin Biosciences, Inc. | Maximum                
Finite-Lived Intangible Assets [Line Items]                
Potential sales milestone payments         17,000      
Assets acquisition required milestone payments         $ 15,000      
Origin-Sentynl APA                
Finite-Lived Intangible Assets [Line Items]                
Assets acquisition required milestone payments   $ 1,000            
Derecognition of capitalized intangible asset net.   $ 13,500   $ 13,500        
Origin-Sentynl APA | Maximum                
Finite-Lived Intangible Assets [Line Items]                
Potential sales milestone payments             $ 4,500  
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.